Neurotoxins and medicinals for the treatment of Parkinson’s disease. Part 2: dopamine receptors and their agonists

Abstract

Five subtypes (D 1 -D 5 ) of dopamine receptors have been cloned and characterized so far, but the contribution of each particular receptor to the development of Parkinson's disease (PD) has not been completely determined because of the absence of the corresponding selective ligands. However, it has been suggested that the main role in the PD development is played by the D 2 -type receptors. For this reason, the review focuses predominantly on the use of D 2 -agonists as antiparkinsonian agents. The main issues of QSAR for these substances are discussed. 520 0091-150X/05/3910-0520